Indivina (Medroxyprogesterone Acetate, Estradiol Valerate)

• Indivina, a combined estrogen‑progestogen therapy, is indicated for conditions related to estrogen deficiency and hormonal regulation.
• Menopausal hormone therapy: alleviates vasomotor symptoms, prevents bone loss, and improves urogenital health in post‑menopausal women.
• Estrogen deficiency symptoms: restores hormonal balance, reducing hot flashes, night sweats, and mood disturbances.
• Premenstrual syndrome: stabilizes hormonal fluctuations, reducing menstrual‑related discomfort and mood changes.

• Indivina delivers estradiol valerate, which is hydrolyzed to estradiol and binds estrogen receptors to exert estrogenic effects, while medroxyprogesterone acetate binds progesterone receptors, providing progestogenic activity. The combined action suppresses endogenous gonadotropin release, inhibits ovulation, and stabilizes the endometrial lining, thereby replacing deficient hormones and maintaining hormonal homeostasis in women.

Common Side Effects

• Nausea
• Breast tenderness
• Headache
• Weight gain
• Bloating
• Mood changes

Serious or Rare Side Effects

• Venous thromboembolism
• Stroke or transient ischemic attack
• Myocardial infarction
• Liver function abnormalities
• Gallbladder disease
• Increased risk of breast cancer

Precautions

• Cardiovascular assessment: evaluate history of thromboembolic or heart disease before initiating therapy.
• Liver function monitoring: check hepatic enzymes periodically during treatment.
• Breast health surveillance: perform regular clinical examinations and imaging as indicated.
• Diabetes management: monitor blood glucose as hormonal changes may affect glycemic control.
• Smoking cessation: advise patients to stop smoking to reduce vascular risk.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Interactions

Major Interactions (Avoid)

• Concomitant estrogen‑containing products: additive risk of thromboembolic events.
• Anticoagulants (e.g., warfarin): may diminish anticoagulant effectiveness.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations of medroxyprogesterone.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce hormone levels, decreasing efficacy.
• Selective serotonin reuptake inhibitors (e.g., paroxetine): can affect metabolism of estradiol.
• Antihypertensive agents: hormonal therapy may alter blood pressure control.